Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Crocs, Inc. (CROX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Crocs, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.45 (market cap $8.04B), while Crocs, Inc. trades at $134.88 (market cap $6.52B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Crocs, Inc. is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | CROX | |
|---|---|---|
Market Cap | $8.04B | $6.52B |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $132.78 |
52-Week Low | $241.71 | $73.39 |
Enterprise Value | $7.85B | $8.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Crocs (CROX) trades at $130.46, down 1.75% on the day, with strong technical momentum indicated by bullish moving averages and a potential breakout pattern forming. The company has consistently beaten earnings estimates in recent quarters, though 2025 showed a net loss of $81.20M. Strategic partnerships with LEGO and Disney are driving brand innovation, while international growth, particularly in Asia, provides expansion opportunities.
The stock presents a mixed outlook with bullish analyst sentiment (51% buy ratings) and a $131.29 consensus price target offering modest upside. Key risks include recent profitability challenges, high debt levels, and competitive pressures in the footwear sector. Revenue stability and brand strength support long-term potential, but margin recovery remains critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →
